Showing 7181-7190 of 10172 results for "".
- Grassley Urges White House to Finish Sunshine Act Regulationshttps://practicaldermatology.com/news/20130125-grassley_urges_white_house_to_finish_sunshine_act_regulations/2459625/Sen. Chuck Grassley of Iowa today urged the White House to finalize the Physician Payments Sunshine Act regulations that will disclose the financial relationships between drug and medical device companies and doctors. “Congress designed the law so that the data would be publicly available by Sept.
- Survey: Women Want Youthful Skin Over Fancy Wardrobehttps://practicaldermatology.com/news/20130124-survey_women_want_youthful_skin_over_fancy_wardrobe/2459628/The Syneron Consumer Beauty Insights Survey of more than 1,000 women over age 25 reports that 79 percent prefer having youthful skin that would make them feel more confident than a designer wardrobe. Findings also show that only eight percent of women are satisfied with their current appearance. In
- Study: Most Skin-Cancer Apps Unreliablehttps://practicaldermatology.com/news/20130123-study_most_skin-cancer_apps_unreliable/2459630/The University of Pittsburgh studied four smartphone apps that evaluate melanoma by analyzing images submitted by the users. One app works by having a board-certified dermatologist look at the photos, while the other three apps analyze the images by computer algorithm. The best-performing of the com
- MedXSafe Phone App Launches for STD Awarenesshttps://practicaldermatology.com/news/20130117-medxsafe_phone_app_launches_for_std_awareness/2459634/Giffen Solutions Inc. released MedXSafe, a new feature to its popular MedXCom Patient platform. Doctors, college health centers, or local health clinics can test for STDs and sign off on MedXSafe that a patient is free of STDs as
- Lancer Skincare Launches At-Home Producthttps://practicaldermatology.com/news/20130117-lancer_skincare_launches_at-home_product/2459635/The Lancer Skincare collection now includes the Microcurrent Powerboost, a hand-held device to help tone, tighten, and correct imbalances in the skin. According to the company, the Microcurrent Powerboost allows daily skincare products to b
- CeraVe Sun Care Partners with Olympic Swimmer Rebecca Sonihttps://practicaldermatology.com/news/20130115-cerave_sun_care_partners_with_olympic_swimmer_rebecca_soni/2459637/CeraVe Sun Care, a new line by Valeant Pharmaceuticals North America LLC, will partner with swimmer Rebecca Soni, six-time US Olympic medalist and World Record holder in the 100- and 200-meter breaststroke, as the face of the brand in 2013. The CeraVe
- Women's Dermatologic Society Event January 15https://practicaldermatology.com/news/20130111-womens_dermatologic_society_event_january_15/2459640/The Women's Dermatologic Society, sponsored by Glytone, will hold a “Look Before You Leap” Media Day 2013 on January 15, a series of desk-side appointments with the editorial community focusing on the pitfalls, complications, problems, and myths surrounding skin care and dermatology topics. Founded
- Jan Marini Skin Research Launches Regeneration Boosterhttps://practicaldermatology.com/news/20130110-jan_marini_skin_research_launches_regeneration_booster/2459643/Jan Marini Skin Research released its all-new Regeneration Booster. Cycloastragenol, TGF Beta-1, multiple beneficial growth factors, and four advanced anti-aging peptides are combined with coenzyme Q10 and additional antioxidants to reduce the a
- Allergan Acquires SkinMedicahttps://practicaldermatology.com/news/20121221-allergan_acquires_skinmedica/2459654/Allergan, Inc. completed the acquisition of SkinMedica, Inc. Under the terms of the agreement, which was first announced on November 16, 2012, Allergan paid approximately $350 million (subject to certain adjustments) for the business, which inclu
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in